Bone and Parathyroid Strategies for Endocrinologists-Phosphatonins: From Discovery to Therapeutics

Video Transcription

Video Summary

Dr. Raj Kumar gave a talk on phosphatonins and their role in regulating phosphate homeostasis. He discussed various conditions associated with abnormal phosphate metabolism, such as tumor-induced osteomalacia (TIO), X-linked hypophosphatemia (XLH), and autosomal-dominant hypophosphatemic rickets. Dr. Kumar explained that TIO is characterized by excessive production of fibroblast growth factor 23 (FGF23) and secreted frizzled-related protein 4 (SFRP4), which result in phosphaturia and inhibition of 1-alpha-hydroxylase activity. He also mentioned the role of FGF23 in regulating phosphate transport and 125-dihydroxyvitamin D3 synthesis. Dr. Kumar emphasized the importance of diagnosing and treating hypophosphatemia, as low phosphate levels can lead to rhabdomyolysis, cardiovascular disease, and bone mineralization defects. He presented data on the use of an antibody against FGF23, called burosamab, which has shown promising results in the treatment of TIO and XLH by increasing serum phosphate concentrations and improving bone mineralization. Dr. Kumar concluded that burosamab could be a potential treatment option for TIO patients with non-resectable tumors and for XLH patients to restore growth and correct skeletal manifestations of the disease.

Keywords

phosphatonins

regulating phosphate homeostasis

tumor-induced osteomalacia

X-linked hypophosphatemia

autosomal-dominant hypophosphatemic rickets

FGF23

phosphate transport

hypophosphatemia

burosamab

bone mineralization